A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2025

Conditions
B Cell LeukemiaB Cell Lymphoma
Interventions
BIOLOGICAL

ICAR19 CAR-T cells

T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD19 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.

Trial Locations (1)

261000

RECRUITING

Weifang People's Hospital, Weifang

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Weifang People's Hospital

OTHER

lead

Immune Cell, Inc.

INDUSTRY